Methods of treating respiratory disorders

Abstract

A method of treating a hyperoxia induced disease or disorder associated with GSNO deficiency in a subject in need thereof includes administering to the subject a therapeutically effective amount of GSNO or a GSNO promoting agent.

1 . A method of treating a hyperoxia induced disease or disorder associated with GSNO deficiency in a subject in need thereof, the method comprising:
 administering to the subject a therapeutically effective amount of GSNO or a GSNO promoting agent.   
     
     
         2 . The method of  claim 1 , the disease or disorder including at least one of respiratory distress syndrome or bronchopulmonary dysplasia (BDP). 
     
     
         3 . The method of  claim 1 , the subject comprising a prematurely born neonatal human subject. 
     
     
         4 . The method of  claim 1 , wherein the GSNO is aerosolized GSNO. 
     
     
         5 . The method of  claim 2 , the aerosolized GSNO administered to the subject at a dose of about 1 μg/kg to 10 g/kg body weight daily. 
     
     
         6 . The method of  claim 1 , wherein the GSNO promoting agent is a GSNO reductase (GSNOR) inhibiting agent. 
     
     
         7 . The method of  claim 6 , the GSNO reductase inhibiting agent comprising a pyrrole inhibitor of GSNO reductase. 
     
     
         8 . The method of  claim 7 , the pyrrole inhibitor of GSNO reductase comprising a compound having the formula: 
       
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable salts thereof. 
     
     
         9 . The method of  claim 1 , the GSNO promoting agent selected from the group consisting of an ADH inhibitor, an AKR inhibitor and/or a SNO-CoAR inhibitor. 
     
     
         10 . The method of  claim 9 , the AKR inhibitor comprising an AKR1A1 inhibitor. 
     
     
         11 . The method of  claim 1 , the GSNO promoting agent administered to the subject via intraperitoneal administration. 
     
     
         12 . The method of  claim 1 , wherein the GSNO or GSNO promoting agent is administered to a premature subject prior to supplemental oxygen treatment. 
     
     
         13 . The method of  claim 1 , wherein the GSNO or GSNO promoting agent is administered to a premature subject during supplemental oxygen treatment. 
     
     
         14 . The method of  claim 1 , wherein the therapeutically effective amount of GSNO or GSNO promoting agent is the amount effective to increase the level of GSNO in the subject's lung tissue. 
     
     
         15 - 27 . (canceled)